{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:26:46Z","timestamp":1790350006388,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.ymgme.2020.02.006","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T12:09:44Z","timestamp":1582114184000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses"],"prefix":"10.1016","volume":"130","author":[{"given":"Emil","family":"Kakkis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Marsden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2020.02.006_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11926-013-0389-0","article-title":"Mucopolysaccharidoses","volume":"16","author":"Cimaz","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0010","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0015","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0020","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/TACG.S69080","article-title":"Role of elosulfase alfa in mucopolysaccharidosis IVA","volume":"9","author":"Regier","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0035","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","article-title":"A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1258\/000456307780945688","article-title":"Quantitation of urinary glycosaminoglycans using dimethylene blue as a screening technique for the diagnosis of mucopolysaccharidoses - an evaluation","volume":"44","author":"Gray","year":"2007","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0045","doi-asserted-by":"crossref","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","article-title":"Enzyme replacement in a canine model of Hurler syndrome","volume":"91","author":"Shull","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0050","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1006\/bmme.1996.0044","article-title":"Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I","volume":"58","author":"Kakkis","year":"1996","journal-title":"Biochem. Mol. Med."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0055","first-page":"11","article-title":"Measurement of Elevated Concentrations of Urine Keratan Sulfate by UPLC-MSMS in Lysosomal Storage Disorders (LSDs): Comparison of Urine Keratan Sulfate Levels in MPS IVA Versus Other LSDs","volume":"34","author":"Ellsworth","year":"2017","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0060","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/s41436-018-0136-z","article-title":"Disease and subtype specific signatures enable precise diagnosis of the mucopolysaccharidoses","volume":"21","author":"Saville","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0065","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.clinbiochem.2015.03.024","article-title":"Recombinant, truncated B. circulans keratanase-II: description and characterisation of a novel enzyme for use in measuring urinary keratan sulphate levels via LC-MS\/MS in Morquio A syndrome","volume":"48","author":"Steward","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0070","series-title":"GeneReviews\u00ae, Seattle (WA)","article-title":"Mucopolysaccharidosis type I","author":"Clarke","year":"1993"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0075","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1542\/peds.2006-2156","article-title":"Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"120","author":"Wraith","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0080","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymgme.2012.02.003","article-title":"Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis","volume":"106","author":"Dickson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0090","first-page":"2868","article-title":"Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"118","author":"Dickson","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0100","series-title":"Minimal Clinically Important Differences in the Six-Minute Walk Test and the Incremental Shuttle Walking test COPD","first-page":"125","volume":"2","author":"Wise","year":"2005"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0110","series-title":"GeneReviews\u00ae, Seattle (WA)","article-title":"Mucopolysaccharidosis type II","author":"Scarpa","year":"1993"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0115","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2007.03.003","article-title":"Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II","volume":"91","author":"Garcia","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0125","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2174\/138920111795542615","article-title":"Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment","volume":"12","author":"Tomatsu","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1750-1172-6-84","article-title":"Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers","volume":"6","author":"Martell","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0135","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1006\/abio.2000.4940","article-title":"Analytical method for keratan sulfates by high-performance liquid chromatography\/turbo-ionspray tandem mass spectrometry","volume":"290","author":"Oguma","year":"2001","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0140","series-title":"Briefing Document for the Endocrinologic and Metabolic Drugs Advisory Committee (19 November 2013)","article-title":"Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IVA (Morquio A syndrome)","author":"BioMarin","year":"2013"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2741\/4490","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"22","author":"Harmatz","year":"2017","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0150","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S8756-3282(97)00175-0","article-title":"Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI","volume":"21","author":"Byers","year":"1997","journal-title":"Bone"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0155","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1172\/JCI118617","article-title":"Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome","volume":"97","author":"Crawley","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0160","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1172\/JCI119208","article-title":"Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI","volume":"99","author":"Crawley","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0165","doi-asserted-by":"crossref","first-page":"36335","DOI":"10.1074\/jbc.274.51.36335","article-title":"Advantages of using same species enzyme for replacement therapy in a feline model of mucopolysaccharidosis type VI","volume":"274","author":"Bielicki","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0170","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0175","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","article-title":"Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"134A","author":"Swiedler","year":"2005","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0180","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)\u201410-year follow-up of patients who previously participated in an MPS VI Survey Study","volume":"164A","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0185","first-page":"1","article-title":"Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome): 15-year follow-up from the Survey Study","volume":"6","author":"Quartel","year":"2018","journal-title":"J. Inborn Erros Metab. Screen"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0190","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of Sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Montano","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0195","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI119322","article-title":"Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation","volume":"99","author":"Sands","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0200","doi-asserted-by":"crossref","first-page":"43160","DOI":"10.1074\/jbc.M107778200","article-title":"Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII","volume":"276","author":"Sands","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0205","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1073\/pnas.051623698","article-title":"Active site mutant transgene confers tolerance to human beta-glucuronidase without affecting the phenotype of MPS VII mice","volume":"98","author":"Sly","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0210","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1203\/00006450-199906000-00010","article-title":"Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy","volume":"45","author":"Vogler","year":"1999","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0215","doi-asserted-by":"crossref","first-page":"14777","DOI":"10.1073\/pnas.0506892102","article-title":"Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII","volume":"102","author":"Vogler","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0220","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","article-title":"Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival","volume":"39","author":"Vogler","year":"1996","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0230","series-title":"NCT00884949: A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects with Mucopolysaccharidosis IVA","author":"ClinicalTrials.gov","year":"2014"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0235","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","article-title":"Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study","volume":"37","author":"Hendriksz","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0240","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0245","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2020.02.006_bb0250","series-title":"NCT01856218: An Open-Label Phase 1\/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients with Mucopolysaccharidosis Type 7 (MPS 7)","author":"ClinicalTrials.gov","year":"2019"},{"key":"10.1016\/j.ymgme.2020.02.006_bb0255","series-title":"NCT02418455: Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age","author":"ClinicalTrials.gov","year":"2019"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220300561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719220300561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:26:03Z","timestamp":1761089163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719220300561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1096719220300561"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.02.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2020.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}